HealthyDirect · GrowthFit for a long SIP
BANDHAN MID CAP FUND
- NAV
- 19.443
- 29 Oct 2026
- 1Y
- +2.8%
- Trailing CAGR
- AUM
- ₹2,519.21 Cr
- 30 Sept 2026
- Volatility
- Medium
- 15.0% annualized
Buying brief
Should you add this fund?
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 29 Oct 2026
Stance
Fit for a long SIP
Evidence supports keeping this on a shortlist for a multi-year equity SIP.
In three lines
Fits if · Risk-adjusted return sits above the documented risk-free proxy.
Buy checklist
History depth
Watch
4.2 years - usable, still building a track record.
Engine status
Pass
Evidence supports keeping this on a shortlist for a multi-year equity SIP.
Expense ratio
Pass
0.76% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Pass
Peak-to-trough -22.7%. Ask whether you can hold through a similar fall.
Vs category
Fail
6% of rolling 3Y windows beat the category median, same plan and option.
Manager tenure
n/a
Manager not listed.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 26.6% of the portfolio.
Evidence supports a shortlist - confirm with peers before you buy elsewhere.
Before you buy or SIP
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 23%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
If you start a SIP here, diary a 90-day check and an annual review - don’t react to every NAV print.
NAV
Path not in current snapshots
n/a
Returns
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
- 1Y+2.8%
- 3Y+17.4%
- 5Yn/a
- 10Yn/a
- SI+17.1%
SIP XIRR
Equal monthly instalments to latest NAV
- 1Y+7.5%
- 3Y+9.3%
- 5Yn/a
- 10Yn/a
- Since inception
- +17.1%
- Calendar-day CAGR
- Excess 1Y
- +3.0%
- Category median, same plan and option
- 3Y win rate
- +6%
- Windows beating the median
- 3Y percentile
- 44
- Vs comparable share classes
- SIP 3Y XIRR
- +9.3%
- Simulated monthly SIP
- Worst rolling 3Y
- +15.4%
- 300 daily-ending windows
- Median rolling 3Y
- +21.6%
- Calendar-day CAGR
- Positive rolling 5Y
- n/a
- 0 daily-ending windows
Drawdown
Peak to trough from a running NAV high, with the path and recovery episodes.
- Max drawdown
- -22.7%
- Worst peak-to-trough
- Current
- -7.1%
- Below last peak
- Current spell
- 59 days
- Days below latest peak
- Time below peak
- +83%
- NAV observations
Drawdown
Path not in current snapshots
n/a
- Average recovery
- 13 days
- 56 recovered episodes
- Longest recovery
- 415 days
- Trough to prior peak
24 Sept 2024 – 27 May 2026
Trough 7 Apr 2025 · recovered in 415 days
-22.7%
31 Aug 2026 – open
Trough 23 Oct 2026 · not recovered
-11.1%
14 Dec 2022 – 4 May 2023
Trough 28 Mar 2023 · recovered in 37 days
-7.0%
11 Sept 2023 – 16 Nov 2023
Trough 26 Oct 2023 · recovered in 21 days
-6.5%
Dimensions
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
44
Vs category
69
Consistency
15
Risk-adjusted
63
Drawdown
43
Mean
47
Decision
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Healthy
Buying stance
Fit for a long SIP
Evidence supports keeping this on a shortlist for a multi-year equity SIP.
Why this status
- No material deterioration, cost shock, or persistent category underperformance in the current evidence set.
Supporting reads
- Risk-adjusted return sits above the documented risk-free proxy.
Portfolio
30 Sept 2026 · 86 holdings · top 10 are 26.6%.
- Top 5
- 15.7%
- Top 10
- 26.6%
- Largest holding
- 4.0%
- Effective holdings
- 60.2
Apar Industries Ltd
Diversified
4.0%
GE T&D India Ltd
Industrials
3.2%
The Federal Bank Ltd
Financial
3.0%
Reverse Repo
Unspecified
2.9%
Ipca Laboratories Ltd
Healthcare
2.7%
What changed
DECISION
Status moved from HEALTHY to MONITOR.
21 Oct 2026
Worth investigating
Same-category peers with enough history to inspect beside this fund - including tradeoffs.
WhiteOak Capital Mid Cap Fund
WhiteOak Capital Mutual Fund
- 1Y
- +4.5%
- 3Y
- +20.6%
- Vol
- 14.8%
- Max DD
- -19.3%
- Sharpe
- 0.99
- 3Y win
- +100%
- Lower volatility
- Shallower drawdown
- Higher win rate vs category
- Higher trailing returns
Caveat: Higher TER
JM Mid Cap Fund
JM Financial Mutual Fund
- 1Y
- +1.3%
- 3Y
- +18.0%
- Vol
- 16.8%
- Max DD
- -22.5%
- Sharpe
- 0.89
- 3Y win
- +53%
- Shallower drawdown
- Higher win rate vs category
- Higher trailing returns
Caveat: Higher volatility · Higher TER
Helios Mid Cap Fund
Helios Mutual Fund
- 1Y
- +2.2%
- 3Y
- n/a
- Vol
- 16.5%
- Max DD
- -16.7%
- Sharpe
- 0.79
- 3Y win
- n/a
- Shallower drawdown
- Higher win rate vs category
Caveat: Higher volatility · Higher TER · Lower trailing returns
HSBC Midcap Fund
HSBC Mutual Fund
- 1Y
- +10.9%
- 3Y
- +22.2%
- Vol
- 17.2%
- Max DD
- -26.0%
- Sharpe
- 0.93
- 3Y win
- +100%
- Higher win rate vs category
- Higher trailing returns
Caveat: Higher volatility · Deeper drawdown · Higher TER
ICICI Prudential Mid Cap Fund
ICICI Prudential Mutual Fund
- 1Y
- +1.8%
- 3Y
- +19.7%
- Vol
- 17.1%
- Max DD
- -44.0%
- Sharpe
- 0.76
- 3Y win
- +16%
- Higher win rate vs category
- Higher trailing returns
Caveat: Higher volatility · Deeper drawdown · Higher TER